Most recent Trading report: Bristol-Myers Squibb Company (NYSE:BMY)

Ebony Scott
March 20, 2017

(Nasdaq:CTMX) climbed more than 30% to touch a new 52-week high in pre-market trade Monday after the oncology-focused biopharmaceutical company said that it has expanded a collaboration deal with drug giant Bristol-Myers Squibb Co. Acropolis Investment Management LLC now owns 2,815 shares of the biopharmaceutical company's stock valued at $152,000 after buying an additional 495 shares during the period. The RSI oscillates between zero and 100.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, January 26th.

Street analysts have the ability to employ multiple metrics to help calculate target price estimates. There is no concrete way to calculate a price target. The shares have been given a mean Overweight rating keeping in view the consensus of 25 Analysts. The stock has an average rating of "Hold" and a consensus target price of $61.61. The fund owned 597,000 shares of the biopharmaceutical company's stock after selling 4,143,200 shares during the period. Earnings per share serves as an indicator of a company's profitability. Are investors supposed to sell when the stock hits the target? To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road. Jefferies Group LLC reissued a buy rating and set a $69.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, January 20th.

For the ongoing Fiscal Quarter, 34 analysts have an average earnings forecast of $0.48 per share. It is the "top line" or "gross income" figure from which costs are subtracted to determine net income.

According to 31 analysts, the Average Revenue Estimate for the current Fiscal quarter is $2.21 Billion and the Low Revenue estimate is $2.19 Billion, while the High Revenue estimate is $2.26 Billion. On annual basis of EPS, FY 2017 Estimate Trends at current were for $3.09 and for the one month was for $3.09 as compared to three months ago was for $3.35.

FBI director confirms investigation of possible collusion between Trump campaign and Russian Federation
Russian Federation denies it attempted to influence the November 8 Presidential election. Comey privately told lawmakers last week that there was no basis to the charge.

'Power Rangers' Movie Spoilers: Which Character Is A Gay Superhero?
I do hope that Trini's "pivotal" moment is handled well and doesn't spiral into bigots in Alabama banning the movie. Trini's woes are assumed to be "boyfriend problems", but are in fact revealed to be "girlfriend problems".

Liverpool draw "one of the happiest days of my life" - Guardiola
Pep Guardiola claims Manchester City's Champions League failure has only strengthened his belief in his footballing philosophies. And Lallana was apologetic after the match, Klopp says. "They're more emotional than the Germans".

The High Revenue estimate is predicted as 4.92 Billion, while the Low Revenue Estimate prediction stands at 4.55 Billion. BMY's ROA is 13.77%, while industry's average is 10.51%. Moving average strategies are also popular and can be tailored to any time frame, suiting both long term investors and short-term traders.

Insider Trades for Bristol-Myers Squibb Company show that the latest trade was made on 9 Mar 2017 where Von Autenried Paul, the Chief Technology Officer completed a transaction type "Buy" in which 2003 shares were traded at a price of $0. The stock stands almost -24.68% off versus the 52-week high and 24.56% away from the 52-week low. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $77.12.

In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Summit Financial Wealth Advisors LLC now owns 53,864 shares of the biopharmaceutical company's stock valued at $2,904,000 after buying an additional 8,303 shares during the period. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. Moreover, Berenberg issued Downgrade rating for the stock on 11-Aug-16. It has ranged in price between $57.12-$57.582 after having started the session at $57.33 as compared to the previous trading day's close of $57.65. The stock has a market cap of 94.23 Billion. It has a 36-month beta of 1.08, so you might be in for a bumpy ride.

Other reports by GizPress

Discuss This Article